• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Cinqaero (reslizumab) - Articles and news items

Teva’s severe eosinophilic asthma drug Cinqaero wins EU approval

Industry news / 18 August 2016 / Caroline Richards, Editor, European Pharmaceutical Review & Drug Target Review

Cinqaero is a humanised interleukin-5 antagonist monoclonal antibody (IgG4 kappa) for add-on therapy in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus another medicinal product for maintenance treatment…